Therapeutic efficacy of a biosimilar epoetin alfa in hemodialysis patients
Joint Authors
Boubaker, Karimah
Zouaghi, Karim
Harzallah, Amal
Duraydi, Afaf
Ayyari, Muhammad
al-Yunusy, Fathi
Beji, Sumayyah
Bin Musa, Fatimah
Khidr, Adil
Source
Saudi Journal of Kidney Diseases and Transplantation
Issue
Vol. 26, Issue 1 (28 Feb. 2015), pp.78-82, 5 p.
Publisher
Saudi Center for Organ Transplantation
Publication Date
2015-02-28
Country of Publication
Saudi Arabia
No. of Pages
5
Main Subjects
Topics
- Patients
- Therapeutics
- Hemodialysis
- Anemia
- Complications(Medicine)
- Kidney failure
- Recombinant erythropoietin
Abstract EN
Anemia is a frequent complication in patients with chronic kidney disease.
However, human recombinant erythropoietin (rHu-EPO) has revolutionized the management of anemia in chronically dialyzed patients.
Epomax® is a new rHu-EPO alfa manufactured in Tunisia (Medis Laboratories).
The aim of this study was to evaluate the efficacy and tolerance of Epomax® in chronic hemodialysis (HD) patients in a phase-III, multicenter, clinical trial.
Fiftythree HD patients (mean age 47.7 ± 13 years) who received a stable dose of rHu-EPO (Hemax®, a rHu-EPO alfa manufactured by Biosidus Laboratories) subcutaneously were switched to Epomax® via the same route of administration.
At baseline, the mean systolic pressure was 132 ± 18 mm Hg and the mean diastolic pressure was 79 ± 8 mm Hg.
The mean blood hemoglobin was 10.2 g / dL and the median ferritin level was 667 ng/mL.
After a follow-up of 43 days, the mean blood hemoglobin was 10.5 g/dL under the effect of Epomax®.
There was no significant difference in the mean hemoglobin levels between the treatments with both drugs.
Few adverse events were reported during the study.
We conclude that Epomax® was effective at maintaining the hemoglobin levels at target concentrations and was well tolerated in HD patients.
American Psychological Association (APA)
Harzallah, Amal& Zouaghi, Karim& Boubaker, Karimah& Beji, Sumayyah& Bin Musa, Fatimah& Khidr, Adil…[et al.]. 2015. Therapeutic efficacy of a biosimilar epoetin alfa in hemodialysis patients. Saudi Journal of Kidney Diseases and Transplantation،Vol. 26, no. 1, pp.78-82.
https://search.emarefa.net/detail/BIM-442443
Modern Language Association (MLA)
Beji, Sumayyah…[et al.]. Therapeutic efficacy of a biosimilar epoetin alfa in hemodialysis patients. Saudi Journal of Kidney Diseases and Transplantation Vol. 26, no. 1 (Jan. / Feb. 2015), pp.78-82.
https://search.emarefa.net/detail/BIM-442443
American Medical Association (AMA)
Harzallah, Amal& Zouaghi, Karim& Boubaker, Karimah& Beji, Sumayyah& Bin Musa, Fatimah& Khidr, Adil…[et al.]. Therapeutic efficacy of a biosimilar epoetin alfa in hemodialysis patients. Saudi Journal of Kidney Diseases and Transplantation. 2015. Vol. 26, no. 1, pp.78-82.
https://search.emarefa.net/detail/BIM-442443
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references : p. 81-82
Record ID
BIM-442443